Providing due diligence in neurology

Challenge

A venture capital investor needed an assessment of the technical, regulatory and market risks in a neuroscience specialty pharma company developing a range of products through the 505 (b)(2) regulatory pathway.

Solution

We gave an assessment of the likely investor returns under two possible scenarios, and advised on the most likely exit triggers/timings. The client expressed a high level of satisfaction with our work.

Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn
Back

Stay in touch